Sarasota, FL -- (SBWIRE) -- 02/11/2019 -- Published a new report titled "Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug Discovery and Development, Personalized medicine, Diagnostics, and Other Applications): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024". According to the report, global cancer biomarkers market was valued at approximately USD 11,000 million in 2017 and is expected to generate revenue of around USD 26,000 million by end of 2024, growing at a CAGR of around 13% between 2018 and 2024.

Cancer biomarkers are perceptible substances, that are used as an indicator of the biological status of the tumor and hence they are used to analyze the prognostic and diagnostic stages of cancer. The preclusion of cancer by early diagnosing and analyzing diverse cancer biomarkers using various diagnostic techniques is an insightful approach for obtaining speedy results for treatment. These biomarkers are used as menace indicators for a different type of cancers such as breast cancer, lung cancer, blood cancer, ovarian cancer, and prostate cancer, among others. SCC, CEA, NSE Cyfra 21-1, PSA, TPA, CA15-3, BRCA ½, EGF R, etc. are some of the key biomarkers which are widely used.

Request Free Sample Research Report @ https://bit.ly/2URinrW

The global cancer biomarkers market is segmented as biomarker type, cancer type, profiling technology, applications, and by geography. Based on biomarker type, the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on the biomarker type, the protein biomarkers accounted for the topmost share in the global cancer biomarker market in the year 2017. The key factor contributing to the high share of protein biomarkers in the global market is that they have excellent potentials in cancer diagnostics, prognostics, and therapeutic & clinical applications. Moreover, they are easy to afford as they are low in cost in comparison with genetic biomarker tests. The rising focus of biotechnology companies for the new discovery of new biomarkers is also expected to fuel the growth of the segment in the global cancer biomarker market.

Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By type, breast cancer accounted for the largest share followed by lung cancer owing to the high prevalence of these cancers in the global cancer biomarker market in 2017. According to the National Cancer Institute, about 268,670 new cases of breast cancer are projected in 2018, in U.S. only.

Request Free Brochure of This Report: https://bit.ly/2RVneGy

By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies accounted for the largest share in the global cancer biomarker market in 2017. The omic technologies include genomics, proteomics, and other omic technologies. The high-throughput from omics technologies is the key factor contributing towards the high share of the segment in the global market.

Based on applications, the cancer biomarkers market is segmented as drug discovery and development, personalized medicine, diagnostics, and other applications. The diagnostics segment accounted for the largest share in the global cancer biomarker market in 2017. The growing demand for early diagnosis of cancer, acceptance of technically advanced tests, and the growing incidence of cancer are prominent factors contributing towards the high share of diagnostics segment in the cancer biomarkers market globally.

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are key regional segments of global cancer biomarkers market. North America and Europe are anticipated to lead the cancer biomarker market in terms of revenue shares. The Asia Pacific is expected to register high growth in the cancer biomarkers market.

Request For Discount for Cancer Biomarkers Market @https://bit.ly/2N3rIKw

Some of the key players in cancer biomarkers market include Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, and Genomic Health, Inc., among others.

This report segments the global cancer biomarkers market as follows:

Global Cancer Biomarkers Market: Biomarker Type Segment Analysis

Genetic Biomarkers
Protein Biomarkers
Other Cancer Biomarkers

Global Cancer Biomarkers Market: Cancer Type Segment Analysis

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Blood Cancer
Melanoma
Ovarian Cancer
Liver Cancer
Stomach Cancer
Other Cancer Types

Global Cancer Biomarkers Market: Profiling Technology Segment Analysis

Imaging technologies
Omic Technologies
Proteomics
Genomics
Other Omic technologies
Cytogenetics-Based Tests
Immunoassays

Global Cancer Biomarkers Market: Applications Segment Analysis

Drug discovery and Development
Personalized medicine
Diagnostics
Others

Purchase this report now Here: https://bit.ly/2N3rK56

Global Cancer Biomarkers Market: Regional Segment Analysis

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa